International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Special Issue 6
Original Research Article
Burr Hole Craniostomy Versus Minicraniotomy in Chronic Subdural Hematoma: A Comparative Cohort Study
Published
Feb. 28, 2024
Abstract

Background: Chronic subdural hematoma (cSDH) remains a significant neurosurgical challenge, with ongoing debate regarding optimal surgical management. This study compared the outcomes of burr hole craniostomy (BHC) versus minicraniotomy (MC) in treating cSDH. Methods: A retrospective analysis of 100 consecutive patients with unilateral cSDH was conducted between October 2022 and January 2024. Patients were divided into BHC (n=49) and MC (n=51) groups. Outcomes were assessed using the Landriel Ibañez grading system for complications, recurrence rates, and 30-day mortality. Results: Mean patient age was comparable between groups (BHC: 72.6±14.2 years, MC: 72.9±12.4 years). Overall complication rates were lower in the BHC group (14.3% vs 21.6%), while recurrence rates were higher (12.2% vs 5.9%, p=0.09). The 30-day mortality rates were similar (BHC: 2.0%, MC: 1.9%, p=0.50). Neurological outcomes were comparable, with mean GCS scores at discharge of 14.4 and 14.3 for BHC and MC groups respectively (p=0.07). Grade Ib complications were most common in both groups (BHC: 6.1%, MC: 9.8%). Conclusion: While both techniques demonstrated acceptable safety profiles, BHC showed lower complication rates but higher recurrence tendency, whereas MC exhibited lower recurrence rates but higher complications. These findings suggest that surgical approach selection should be individualized based on patient characteristics and hematoma features.

Recommended Articles
Loading Image...
Volume-5, Special Issue 6
Citations
622 Views
253 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved